The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial
Open accessAbstract
Importance: Hospitalized patients with COVID-19 are at risk for venous and arterial thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown. Objective: To evaluate the effects of therapeutic-dose low-molecular-weight heparin (LMWH) vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19. Design, Setting, and Participants: The HEP-COVID multicenter randomized clinical trial recruited hospitalized adult patients with COVID-19 with D-dimer levels more than 4 times the upper limit of normal or sepsis-induced coagulopathy score of 4 or greater from May 8, 2020, through May 14, 2021, at 12 academic centers in the US. Interventions: Patients were randomized to institutional standard prophylactic or intermediate-dose LMWH or unfractionated heparin vs therapeutic-dose enoxaparin, 1 mg/kg subcutaneous, twice daily if creatinine clearance was 30 mL/min/1.73 m2 or greater (0.5 mg/kg twice daily if creatinine clearance was 15-29 mL/min/1.73 m2) throughout hospitalization. Patients were stratified at the time of randomization based on intensive care unit (ICU) or non-ICU status. Main Outcomes and Measures: The primary efficacy outcome was venous thromboembolism (VTE), arterial thromboembolism (ATE), or death from any cause, and the principal safety outcome was major bleeding at 30 ± 2 days. Data were collected and adjudicated locally by blinded investigators via imaging, laboratory, and health record data. Results: Of 257 patients randomized, 253 were included in the analysis (mean [SD] age, 66.7 [14.0] years; men, 136 [53.8%]; women, 117 [46.2%]); 249 patients (98.4%) met inclusion criteria based on D-dimer elevation and 83 patients (32.8%) were stratified as ICU-level care. There were 124 patients (49%) in the standard-dose vs 129 patients (51%) in the therapeutic-dose group. The primary efficacy outcome was met in 52 of 124 patients (41.9%) (28.2% VTE, 3.2% ATE, 25.0% death) with standard-dose heparins vs 37 of 129 patients (28.7%) (11.7% VTE, 3.2% ATE, 19.4% death) with therapeutic-dose LMWH (relative risk [RR], 0.68; 95% CI, 0.49-0.96; P = .03), including a reduction in thromboembolism (29.0% vs 10.9%; RR, 0.37; 95% CI, 0.21-0.66; P < .001). The incidence of major bleeding was 1.6% with standard-dose vs 4.7% with therapeutic-dose heparins (RR, 2.88; 95% CI, 0.59-14.02; P = .17). The primary efficacy outcome was reduced in non-ICU patients (36.1% vs 16.7%; RR, 0.46; 95% CI, 0.27-0.81; P = .004) but not ICU patients (55.3% vs 51.1%; RR, 0.92; 95% CI, 0.62-1.39; P = .71). Conclusions and Relevance: In this randomized clinical trial, therapeutic-dose LMWH reduced major thromboembolism and death compared with institutional standard heparin thromboprophylaxis among inpatients with COVID-19 with very elevated D-dimer levels. The treatment effect was not seen in ICU patients. Trial Registration: ClinicalTrials.gov Identifier: NCT04401293.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,662
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C. D., Ageno, W., Madjid, M., Guo, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.031 · Cited by 2,885
Self-citationCRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., Merdji, H., Clere-Jehl, R., Schenck, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06062-x · Cited by 2,792
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study
Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A. S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2003 · Cited by 2,274
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.041 · Cited by 1,601
Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence
Poissy, J., Goutay, J., Caplan, M., Parmentier, E., Duburcq, T., Lassalle, F., Jeanpierre, E., Rauch, A., Labreuche, J., Susen, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047430 · Cited by 1,071
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
The ATTACC, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105911 · Cited by 1,046
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103417 · Cited by 941
Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System
Bilaloglu, S., Aphinyanaphongs, Y., Jones, S., Iturrate, E., Hochman, J., & Berger, J. S. (2020) · JAMA · doi:10.1001/jama.2020.13372 · Cited by 818
Cuker, A., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Linkins, L. A., Rodner, S. B., Selleng, S., Warkentin, T. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024489 · Cited by 750
Lax, S. F., Skok, K., Zechner, P., Kessler, H. H., Kaufmann, N., Koelblinger, C., Vander, K., Bargfrieder, U., & Trauner, M. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2566 · Cited by 730
Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., Levi, M., Samama, C. M., Thachil, J., Giannis, D., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14929 · Cited by 657
Self-citationINSPIRATION Investigators, Mazloomzadeh, S., Khaleghparast, S., Ghadrdoost, B., Mousavizadeh, M., Baay, M. R., Noohi, F., Sharifnia, H., Ahmadi, A., Tavan, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.4152 · Cited by 625
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P. R., Goligher, E. C., Berger, J. S., Neal, M. D., McVerry, B. J., Nicolau, J. C., Gong, M. N., et al. (n.d.) · Bern Open Repository and Information System (University of Bern) · doi:10.17863/cam.76384 · Cited by 581
Coagulopathy of Coronavirus Disease 2019
Iba, T., Levy, J. H., Levi, M., Connors, J. M., & Thachil, J. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004458 · Cited by 534
Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation
Iba, T., Levy, J. H., Warkentin, T. E., Thachil, J., van der Poll, T., & Levi, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14578 · Cited by 531
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
Nopp, S., Moik, F., Jilma, B., Pabinger, I., & Ay, C. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12439 · Cited by 489
Lopes, R. D., de Barros e Silva, P. G. M., Furtado, R. H. M., Macedo, A. V. S., Bronhara, B., Damiani, L. P., Barbosa, L. M., de Aveiro Morata, J., Ramacciotti, E., de Aquino Martins, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01203-4 · Cited by 481
Sholzberg, M., Tang, G. H., Rahhal, H., AlHamzah, M., Kreuziger, L. B., Áinle, F. N., Alomran, F., Alayed, K., Alsheef, M., AlSumait, F., et al. (2021) · BMJ · doi:10.1136/bmj.n2400 · Cited by 380
Symmetric Group Sequential Test Designs
Emerson, S. S., & Fleming, T. R. (1989) · Biometrics · doi:10.2307/2531692 · Cited by 155
Tritschler, T., Mathieu, M., Skeith, L., Rodger, M. A., Middeldorp, S., Brighton, T., Sandset, P. M., Kahn, S. R., Angus, D., Blondon, M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15094 · Cited by 97
Self-citationThe Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review
Gozzo, L., Viale, P., Longo, L., Vitale, D. C., & Drago, F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01307 · Cited by 89
Emergence of institutional antithrombotic protocols for coronavirus 2019
Cohoon, K. P., Mahé, G., Tafur, A. J., & Spyropoulos, A. C. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12358 · Cited by 58
Self-citationHospitalized COVID-19 Patients and Venous Thromboembolism
Spyropoulos, A. C., & Weitz, J. I. (2020) · Circulation · doi:10.1161/circulationaha.120.048020 · Cited by 56
Self-citationFernández‐Capitán, C., Barba, R., Díaz-Pedroche, M. D. C., Sigüenza, P., Rodríguez, P. D., Siniscalchi, C., Pedrajas, J. M., Farfán‐Sedano, A. I., Olivera, P. E., Cuervo, C. G., et al. (2020) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0040-1718402 · Cited by 53
Self-citationRaskob, G. E., Spyropoulos, A. C., Cohen, A. T., Weitz, J. I., Ageno, W., Sanctis, Y. D., Lu, W., Xu, J., Albanese, J., Sugarmann, C., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019459 · Cited by 44
Self-citationCardillo, G., Viggiano, G. V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., Agrusta, F., Bellizzi, A., Amitrano, M., Iannuzzo, M., et al. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s285214 · Cited by 34
Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Sharifova, G., Cohen, M. C., Lund, J. M., Mignatti, A., Gianos, E., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1475-2351 · Cited by 9
Self-citation
Cited by
Katsoularis, I., Fonseca-Rodríguez, O., Farrington, P., Jerndal, H., Lundevaller, E. H., Sund, M., Lindmark, K., & Fors Connolly, A.-M. (2022) · BMJ · doi:10.1136/bmj-2021-069590 · Cited by 388
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Kernan, K. F., Schulert, G. S., Seo, P., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42062 · Cited by 296
Gorog, D. A., Storey, R. F., Gurbel, P. A., Tantry, U. S., Berger, J. S., Chan, M. Y., Duerschmied, D., Smyth, S. S., Parker, W. A. E., Ajjan, R. A., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00665-7 · Cited by 286
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
Hróbjartsson, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081660 · Cited by 171
Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future
Hu, M.-L., Pan, Y.-R., Yong, Y.-Y., Liu, Y., Yu, L., Qin, D.-L., Qiao, G., Law, B. Y.-K., Wu, J.-M., Zhou, X.-G., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102078 · Cited by 44
Metadata
- Authors
- Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Mignatti, A., Gianos, E., Cohen, M., Sharifova, G., Lund, J. M., Tafur, A., Lewis, P. A., Cohoon, K. P., Rahman, H., Sison, C. P., Lesser, M. L., Ochani, K., Agrawal, N., Hsia, J., Anderson, V. E., Bonaca, M., Halperin, J. L., Weitz, J. I., HEP-COVID Investigators, Ohanesian, L., Glater, M., Ho, C., Iakovou, A., Ying, D., Dastagir, M., Convissar, A., Aujla, S., Mathew, E., Thiyagarajan, V., Lewis, T., Gruberg, L., Maccaro, P., Kuziw, D., Pandhi, B., Surguladze, G., Eapen, A. M., Pantea, A., Suen, P., Flynt, J., Krzyzak, M., Sharma, K., Steadham, A., McLean, S. L., Herring, K., Maroney, K., Zorriasateyn, K., Vargas, B., Durante, M., Bhokary, U., Pierchala, L., Fisher, E. A., Oxenberg, D. L., Sabados, A., Chaudhary, O. A., Schultz, S., Cotey, S., Hess, C., Cruse, H., Uy, D., Sharma, S., Molina, K., Jagat, D., & Dehali, B.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2021-12-01
- Volume
- 181
- Issue
- 12
- Pages
- 1612
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W3202637221
- Cited by
- 461
- References
- 30
- FWCI
- 72.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.